EBR Systems Faces Adoption Challenges Despite CHRISTUS Health Agreement

Strategic Expansion into Major US Hospital Network

EBR Systems (ASX:EBR) has secured a pivotal three-year purchasing agreement with CHRISTUS Health, the ninth-largest hospital network in the United States. This deal establishes a direct procurement pathway for EBR’s WiSE cardiac resynchronisation therapy (CRT) system across 66 hospitals primarily located in Texas, Louisiana, and New Mexico. CHRISTUS Health’s network spans over 600 centres and employs 15,000 clinicians, providing EBR with a significant institutional footprint to accelerate its US commercial rollout.

John McCutcheon, EBR’s CEO, emphasised the alignment with CHRISTUS’s patient-centred care ethos, highlighting the agreement’s role in widening access to leadless CRT therapy. This wireless pacing technology aims to overcome complications associated with traditional lead-based devices by stimulating the heart’s left ventricle endocardially via a rice-grain-sized implant.

Broader US Market Penetration Amid Growing Commercial Momentum

The CHRISTUS Health deal follows a similar purchasing agreement EBR secured recently with Advocate Health, covering 69 hospitals across eight states, underscoring a pattern of gaining traction within large non-profit health systems. These partnerships are critical as EBR continues to build commercial momentum in the US, where the WiSE CRT System remains its sole market-approved product.

EBR’s US rollout has shown promising signs, with implant volumes more than doubling in Q1 2026 and preliminary revenues reaching approximately US$2.4 million. The company’s ability to engage directly with physicians within these networks is expected to facilitate adoption and training, key factors in driving utilisation across multiple sites.

Technology Offering and Market Positioning

EBR’s WiSE system is unique in the cardiac pacing landscape, offering wireless, endocardial stimulation that potentially improves anatomical pacing accuracy and reduces complications linked to coronary sinus leads. However, the device remains investigational in most markets and is currently only commercially available in the US, pending regulatory approvals elsewhere, such as the recent priority review granted by Australia’s Therapeutic Goods Administration.

While the financial terms of the CHRISTUS agreement were not disclosed, the arrangement signals growing institutional acceptance of EBR’s technology. The company’s ongoing efforts to expand hospital access through faith-based and mission-driven networks like CHRISTUS could bolster its competitive position in the evolving cardiac device market.